BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32968751)

  • 1. Probing arsenic trioxide (ATO) treated leukemia cell elasticities using atomic force microscopy.
    Fortier H; Gies V; Variola F; Wang C; Zou S
    Anal Methods; 2020 Oct; 12(39):4734-4741. PubMed ID: 32968751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
    Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
    Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
    Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
    Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
    Zaki Dizaji M; Ghaffari SH; Hosseini E; Alizadeh N; Rostami S; Momeny M; Alimoghaddam K; Ghavamzadeh A
    Asia Pac J Clin Oncol; 2017 Apr; 13(2):e21-e30. PubMed ID: 27770503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
    Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
    Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of Acute Promyelocytic Leukemia Cells to Arsenic Trioxide Via Blunting PI3K/NF-κB Axis.
    Sayyadi M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Abolghasemi H; Anoushirvani AA; Bashash D
    Arch Med Res; 2020 Oct; 51(7):636-644. PubMed ID: 32553459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
    Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
    Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
    Wang QQ; Hua HY; Naranmandura H; Zhu HH
    Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells.
    Hu J; Sun Q; Fang W; Wang Q
    Cell Mol Biol (Noisy-le-grand); 2019 Apr; 65(4):97-100. PubMed ID: 31078158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of simultaneous administration of arsenic trioxide and microvesicles derived from human bone marrow mesenchymal stem cells on cell proliferation and apoptosis of acute myeloid leukemia cell line.
    Abbaszade Dibavar M; Soleimani M; Atashi A; Rassaei N; Amiri S
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S138-S146. PubMed ID: 30600718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
    Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
    Xu W; Li X; Quan L; Yao J; Mu G; Guo J; Wang Y
    Leuk Lymphoma; 2018 Mar; 59(3):650-659. PubMed ID: 28679299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
    Cao F; Li X; Yang Y; Fang H; Qu H; Chang N; Ma Q; Cao W; Zhou J; Wang W
    OMICS; 2019 Feb; 23(2):119-130. PubMed ID: 30767729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
    Bankar A; Korula A; Kulkarni UP; Devasia AJ; Na F; Lionel S; Abraham A; Balasubramanian P; Janet NB; Nair SC; S S; Jeyaseelan V; N J; Prasad J; George B; Mathews V
    Br J Haematol; 2020 Apr; 189(2):269-278. PubMed ID: 31863602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
    Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
    Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.
    Lunghi P; Tabilio A; Lo-Coco F; Pelicci PG; Bonati A
    Leukemia; 2005 Feb; 19(2):234-44. PubMed ID: 15538402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.